Evaluating the antifracture efficacy of bisphosphonates.
Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...
Autores principales: | Pazianas, M, Epstein, S, Zaidi, M |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
2009
|
Ejemplares similares
-
Antifracture agents for prostate cancer patients on androgen deprivation therapy
por: Bhupendra P Singh, et al.
Publicado: (2010-01-01) -
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
por: Angelo Fassio, et al.
Publicado: (2024-04-01) -
Safety of bisphosphonates.
por: Pazianas, M, et al.
Publicado: (2011) -
Bisphosphonates and bone quality.
por: Pazianas, M, et al.
Publicado: (2014) -
Atrial fibrillation and bisphosphonate therapy.
por: Pazianas, M, et al.
Publicado: (2010)